Diagnosis and management of atrial fibrillation by primary care physicians in Italy: A retrospective, observational analysis

Clinical Drug Investigation

Volumn 32, Issue 11, 2012, Pages 771-777

  Piccinocchi, Gaetano ^a,b   Laringe, Matteo ^a,b   Guillaro, Bruno ^a,b   Arpino, Giovanni ^a,b   Piccinocchi, Roberto ^c   Nigro, Gerardo ^d   Calabrò, Paolo ^d  

^a Cooperative of Primary Care Physicians ^*  (Italy)

^b Societa Italiana di Medicina Generale   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOEMBOLISM; VASCULAR DISEASE;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; ITALY; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873436718     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-012-0005-5     Document Type: Article

References (37)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5.
2. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N.
3. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
4. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70.
5. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32(3):803-8.
6. Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28(2):316-21.
7. Kilander L, Andren B, Nyman H, et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke. 1998;29(9):1816-20.
8. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501.
9. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123(7):638-645 e4.
10. Tulner LR, Van Campen JP, Kuper IM, et al. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging. 2010;27(1):39-50.
11. Klein D, Levine M. Are family physicians using the CHADS score? Is it useful for assessing risk of stroke in patients with atrial fibrillation? Can Fam Physician. 2011;57(8):e305-9.
12. Rodriguez-Manero M, Cordero A, Bertomeu-Gonzalez V, et al. Impact of new criteria for anticoagulant treatment in atrial fibrillation. Rev Esp Cardiol. 2011;64(8):649-53.
13. Nieuwlaat R, Barker L, Kim YK, et al. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res. 2010;125(4):e128-31.
14. Cricelli C, Mazzaglia G, Samani F, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med. 2003;25(3):254-7.
15. Filippi A, Vanuzzo D, Bignamini AA, et al. Computerized general practice databases provide quick and cost-effective information on the prevalence of angina pectoris. Ital Heart J. 2005;6(1):49-51.
16. Filippi A, Bignamini AA, Sessa E, et al. Secondary prevention of stroke in Italy: a cross-sectional survey in family practice. Stroke. 2003;34(4):1010-4.
17. ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification). 6th ed. 2006/Practice Management Information Corporation (PMIC) ed. Published Los Angeles, CA.
18. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.
19. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100.
20. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401.
21. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8.
22. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949-53.
23. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ. 2007;335(7616):383.
24. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469-73.
25. Bilato C, Corti MC, Baggio G, et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). Am J Cardiol. 2009;104(8):1092-7.
26. Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9(8):1460-7.
27. Olesen JB, Pisters R, Roldans V, et al. The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use. J Am Coll Cardiol 2012;59(2):194-195; author reply 5.
28. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27(24):3018-26.
29. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927-34.
30. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation. 1998;97(13):1231-3.
31. Mazzaglia G, Filippi A, Alacqua M, et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost. 2010;103(5):968-75.
32. Hylek EM. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost. 2008;100(1):16-7.
33. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13(5):723-46.
34. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106(4):739-49.
35. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503.
36. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297-305.
37. Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol. 2004;57(6):798-806.